ANGLE Plc (ANGLE) is a medical diagnostic company that offers cancer diagnostics and fetal health products. The company develops products for use in rare cell diagnostics that enable early, accurate identification of an individual’s condition for the prevention, treatment and monitoring of disease. Its product Parsortix cell separation system, which captures very rare circulating tumor cells in cancer patient blood. ANGLE’s Parsortix cell separation system uses a microfluidic technology in the form of a one-time use cassette to capture and then harvest circulating tumor cells (CTCs) from blood. Its cassette captures CTCs based on their less deformable nature and larger size compared to other blood components. The company provides liquid biopsy (blood test) that enables the detection and investigation of mutations in the patient's cancer for personalized cancer care. Its harvested CTCs have a range of applications such as diagnosis, prognosis, mutational analysis and drug selection, drug development, assessment of treatment effectiveness and remission monitoring. The company has operations in the US and the UK. ANGLE is headquartered in Guildford, Surrey, the UK.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
The report analyzes all pipeline products in development for the company ANGLE Plc
The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
The report provides detailed description of products in development, technical specification and functions
The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
To formulate effective Research & Development strategies
Develop market-entry and market expansion strategies
Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note:Some sections may be missing if data is unavailable for the company
ANGLE Plc Company Overview
ANGLE Plc Company Snapshot
ANGLE Plc Pipeline Products and Ongoing Clinical Trials Overview
ANGLE Plc – Pipeline Analysis Overview
ANGLE Plc - Key Facts
ANGLE Plc - Major Products and Services
ANGLE Plc Pipeline Products by Development Stage
ANGLE Plc Ongoing Clinical Trials by Trial Status
ANGLE Plc Pipeline Products Overview
ALENA System - Abscesses
ALENA System - Abscesses Product Overview
ALENA System - Antibiotic Resistance
ALENA System - Antibiotic Resistance Product Overview
ALENA System - Bone & Joint Infections
ALENA System - Bone & Joint Infections Product Overview
ALENA System - Sepsis
ALENA System - Sepsis Product Overview
Cardiac Troponin Biomarker Kit
Cardiac Troponin Biomarker Kit Product Overview
CTC-Based HER2 Assay
CTC-Based HER2 Assay Product Overview
HyCEAD Ziplex System - Ovarian Cancer Assay
HyCEAD Ziplex System - Ovarian Cancer Assay Product Overview
HyCEAD Ziplex System - Ovarian Cancer Assay Clinical Trial
Table 23: HyCEAD Ziplex System - Ovarian Cancer Assay - Product Status
Table 24: HyCEAD Ziplex System - Ovarian Cancer Assay - Product Description
Table 25: HyCEAD Ziplex System - Ovarian Cancer Assay - Study Evaluates the Use of ANGLE's Combined Parsortix and HyCEAD Ziplex Platforms as a Simple Blood Test to Detect the Presence of Ovarian Cancer
Table 26: Landscape+ Ovarian Assay - Product Status
Table 28: Landscape+ Ovarian Assay - Study Evaluates the Use of ANGLE's Combined Parsortix and HyCEAD Ziplex Platforms as a Simple Blood Test to Detect the Presence of Ovarian Cancer
Table 31: Multiplex Ovarian Cancer Biomarker Assay - Product Status
Table 32: Multiplex Ovarian Cancer Biomarker Assay - Product Description
Table 33: Multiplex Pathogen Detection Test - Product Status
Table 34: Multiplex Pathogen Detection Test - Product Description
Table 35: Parsortix GEN2 - Product Status
Table 36: Parsortix GEN2 - Product Description
Table 37: Parsortix System - Renal Carcinoma - Product Status
Table 38: Parsortix System - Renal Carcinoma - Product Description
Table 39: Parsortix-Based Test - Brain Metastasis - Product Status
Table 40: Parsortix-Based Test - Brain Metastasis - Product Description
Table 41: Parsortix-Based Test - Colorectal Cancer - Product Status
Table 42: Parsortix-Based Test - Colorectal Cancer - Product Description
Table 43: Parsortix-Based Test - Head & Neck Cancer - Product Status
Table 44: Parsortix-Based Test - Head & Neck Cancer - Product Description
Table 45: Parsortix-Based Test - Lung Cancer - Product Status
Table 46: Parsortix-Based Test - Lung Cancer - Product Description
Table 47: Parsortix-Based Test - Lung Cancer - Evaluation of Non-small Cell Lung Carcinoma Genetic Heterogeneity in Patients with Operable Early Stage Disease and Prediction of Clinical Relapse Using a Personalized
Liquid Biopsy
Table 48: Parsortix-Based Test - Pancreatic Cancer - Product Status
Table 49: Parsortix-Based Test - Pancreatic Cancer - Product Description
Table 50: Parsortix-Based Test - Prostate Cancer - Product Status
Table 51: Parsortix-Based Test - Prostate Cancer - Product Description
Table 52: Parsortix-Based Test - Prostate Cancer - Study to Evaluate the Efficacy of Parsortix-Based CTC Blood Test in Detecting the Progression of Prostate Cancer
Table 53: Parsortix-Based Test - Prostate Cancer - Study to Investigate the Parsortix System for the Detection of Prostate Cancer and Prediction of its Severity
Table 54: Point-Of-Care Diagnostic Test - TBI - Product Status
Table 55: Point-Of-Care Diagnostic Test - TBI - Product Description
Table 56: Rapid Blood Test - Intracranial Hemorrhage - Product Status